A-Share Announcement Highlights | Guangdong Hec Technology Holding (600673.SH) and Shandong Gold Mining (600547.SH) Announce Share Buyback Plans
Shandong Gold Mining announced that Wang Chenglong, the company's chairman, proposed that the company use its own funds and self-raised funds to repurchase part of its A-shares through centralized bidding, with a total repurchase amount of RMB 300 million to RMB 400 million. All repurchased shares will be used for cancellation and to reduce the company's registered capital.
Today's Focus
1. Guangdong Hec Technology Holding: Controlling shareholder proposes share buyback of RMB 600 million to RMB 1.2 billion
Guangdong Hec Technology Holding announced that its controlling shareholder, Shenzhen Guangdong Hec Technology Holding Industrial, has proposed that the company repurchase its A-shares through the Shanghai Stock Exchange system via centralized bidding using its own funds or self-raised funds, with the repurchase amount no less than RMB 600 million and no more than RMB 1.2 billion. The repurchase price shall not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board resolution, and the implementation period shall be within 6 months after approval by the board of directors. Shenzhen Guangdong Hec Technology Holding Industrial has committed to actively urging the company to convene a board meeting as soon as possible to deliberate on the repurchase matter.
2. Shandong Gold Mining: Chairman proposes buyback of RMB 300 million to RMB 400 million of A-shares
Shandong Gold Mining announced that its chairman, Wang Chenglong, has proposed that the company repurchase part of its A-shares through centralized bidding using its own funds and self-raised funds, with the total repurchase amount ranging from RMB 300 million to RMB 400 million. The repurchased shares will all be used for cancellation and reduction of the company's registered capital. The upper limit of the repurchase price shall not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board resolution approving the repurchase plan, and the repurchase period shall be within 12 months from the date of approval of the plan by the shareholders' meeting.
3. Suzhou Institute of Building Science Group: Planning major matter, shares suspended
Suzhou Institute of Building Science Group announced that it has been notified by relevant parties that a major matter involving the company is being planned. Given the significant uncertainty of this matter, in order to ensure fair information disclosure and protect investors' interests, the company's shares will be suspended from trading starting from the market open on September 30, 2026, with the suspension expected to last no more than 2 trading days. Currently, the matter is still in the planning stage, and whether it can be implemented remains highly uncertain.
4. Jiangsu Nhwa Pharmaceutical: Grants Somnivera exclusive rights to an investigational innovative drug for sleep disorders, eligible for up to USD 507 million in milestone payments
Jiangsu Nhwa Pharmaceutical announced that it has entered into an exclusive license agreement with Somnivera, granting it exclusive rights to develop, manufacture, and commercialize an investigational drug worldwide excluding mainland China, Hong Kong, Macau, and Taiwan. The investigational drug is a Class 1 innovative drug independently developed by the company with independent intellectual property rights, intended for the treatment of sleep disorders. Somnivera will pay an upfront payment of USD 10.5 million, and the company is eligible for up to USD 507 million in milestone payments, as well as tiered royalties calculated at a percentage ranging from single-digit to low double-digit percentages of net sales. The company has also acquired a 15% equity stake in Somnivera through its wholly-owned subsidiary Hong Kong Nhwa.
5. Yangtze Optical Electronic: Signs RMB 147 million polarization-maintaining fiber product sales order
Yangtze Optical Electronic announced that it recently received a purchase order from a customer for polarization-maintaining fiber products, with a total amount tentatively set at RMB 147 million (tax inclusive). This transaction is a routine business sales order of the company, and if successfully implemented, it is expected to have a positive impact on the company's operating performance. The unit price of the order is a tentative price, and the final price will be calculated according to the framework agreement. The company has been exempted from disclosing certain information such as the customer's name and product specifications.
Buybacks % Increases/Decreases in Holdings
1. China Automotive Engineering Research Institute: Controlling shareholder plans to increase holdings by RMB 60 million to RMB 120 million
2. Hainan Expressway: Controlling shareholder plans to increase holdings by RMB 45 million to RMB 90 million
3. Sanbo Hospital Management: Shareholder holding more than 5% has cumulatively reduced holdings by 1.69%
4. ShuYu Civilian Pharmacy Corp.,Ltd.: Shuyu Jinyun has cumulatively reduced holdings by 1.47%
5. Jiangsu Gian Technology: Multiple shareholders collectively reduced holdings by 473,600 shares
Major Contracts
1. China State Construction Engineering Corporation: Recently awarded major projects totaling RMB 14.04 billion
2. Anhui Construction Engineering Group Corporation: Jointly won multiple major projects totaling approximately RMB 10.071 billion
3. BOMESC Offshore Engineering: Wholly-owned subsidiary signs FPSO topside module construction contract worth RMB 1.6 billion to RMB 2.1 billion
4. Suzhou Gold Mantis Construction Decoration: Won engineering projects totaling approximately RMB 343 million
This article is reprinted from Tencent Stock Picker, edited by GMTEight: Chen Wenfang.
Related Articles

LIVZON PHARMA (01513): Abnormal Fluctuations in A-Share Trading; No Major Matters That Should Be Disclosed but Have Not Been Disclosed

CF PHARMTECH (02652) repurchased 67,900 shares for HKD 489,100 on September 29.

ART GROUP HOLD (00565) issues profit warning, expects annual loss attributable to shareholders of not more than HK$17 million, turning from profit to loss year-on-year.
LIVZON PHARMA (01513): Abnormal Fluctuations in A-Share Trading; No Major Matters That Should Be Disclosed but Have Not Been Disclosed

CF PHARMTECH (02652) repurchased 67,900 shares for HKD 489,100 on September 29.

ART GROUP HOLD (00565) issues profit warning, expects annual loss attributable to shareholders of not more than HK$17 million, turning from profit to loss year-on-year.






